Thrombotic Thrombocytopenic Purpura (TTP)

Overview

Thrombotic Thrombocytopenic Purpura (TTP) is a rare but serious blood disorder in which blood clots form in small blood vessels throughout the body. These tiny clots use up platelets, lower platelet counts, and can block blood flow to vital organs, causing organ damage if not treated quickly. TTP is considered a medical emergency, but with prompt therapy, most people recover.

There are two major forms:

Immune‑mediated TTP (iTTP) – caused by antibodies attacking an enzyme called ADAMTS13.

Hereditary TTP – a very rare form due to an inherited gene mutation affecting the same enzyme.

Causes

TTP occurs when the body lacks adequate ADAMTS13—the enzyme responsible for cutting large von Willebrand factor (vWF) molecules. Without this enzyme, unusually large vWF “strings” collect in the bloodstream and cause platelets to stick together, forming micro‑clots.

Low ADAMTS13 levels may be caused by:

Autoantibodies

that block or destroy the enzyme (immune‑mediated TTP).

Genetic mutations

affecting ADAMTS13 (hereditary TTP).

Symptoms

TTP symptoms often develop suddenly and can worsen rapidly. Common signs include:

Neurologic symptoms

such as headache, confusion, trouble speaking, or seizures

Abdominal pain

nausea, or vomiting

Petechiae, purpura, or easy bruising

from low platelets

Fatigue

or shortness of breath

Fever

Signs of Organ Involvement

kidney issues, chest pain, or stroke‑like symptoms

Any sudden combination of neurological symptoms and thrombocytopenia should be treated as urgent until proven otherwise.

How TTP is Diagnosed

TTP is diagnosed using a combination of symptoms, labs, and scoring tools. Providers typically evaluate:

Platelet count

(usually very low)

Evidence of hemolysis

(red blood cell destruction)

Creatinine levels

ADAMTS13 activity

when available

Because TTP progresses rapidly, treatment is started immediately if suspicion is high, even before final test results return.

Clinical prediction scores using platelet count and kidney function help guide early decisions and reduce delays in therapy.

Treatment Options

TTP requires urgent treatment to prevent severe organ damage.

This is the cornerstone of TTP treatment. Plasma exchange removes harmful antibodies and replaces missing ADAMTS13. Survival rates have improved from nearly zero to ~93% with this therapy.

Corticosteroids—reduce immune system activity.
Rituximab—targets immune cells producing the damaging antibodies.

A targeted therapy (“nanobody”) that blocks platelets from binding to vWF. When used with plasma exchange and immunosuppression, it:

Speeds platelet recovery
Reduces risk of early relapse

Monitoring for organ injury
Red blood cell transfusions if needed
Avoiding platelet transfusions unless life‑threatening bleeding occurs (they can worsen clotting in TTP)

Living With & Monitoring TTP

Even after recovery, people with TTP need:

Regular follow-up

to monitor platelet counts and ADAMTS13 levels

Awareness of relapse symptoms

(confusion, bruising, headache, abdominal pain)

Prompt evaluation

if symptoms return

Most people recover fully with proper, timely treatment.

When To See Your Provider

Seek urgent medical care if you experience:

Sudden severe headache or confusion

New neurologic symptoms

(weakness, trouble speaking)

Unusual bruising or bleeding

Dark urine or signs of anemia

These may indicate active or recurring TTP and require immediate treatment.

Why Choose Illinois CancerCare

A blood disorder diagnosis can feel overwhelming. At Illinois CancerCare, we are committed to ensuring you never have to face it alone. Providing advanced, comprehensive hematology and oncology care for our patients is at the heart of everything we do. Since 1977, our specialists have focused on individualized, evidence-based treatment plans, access to world-class clinical trials, and thorough follow-up. With Illinois CancerCare, you can move forward with confidence knowing trusted expertise and compassionate support are always close to home.‑based treatment plans, access to world‑class clinical trials, and thorough follow‑up.

Sources & Patient Friendly References

Information sourced from NCI (National Cancer Institute) and Mayo Clinic.